Bristol-Myers Squibb Company and Catalent, Inc. today announced that Catalent has agreed to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy.
Bristol-Myers Squibb Company and Catalent, Inc. today announced that Catalent has agreed to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy.
Alessandro Maselli was appointed Catalent’s President and Chief Executive Officer in July 2022. He previously served as the company’s President & Chief Operating Officer since February 2019. Mr. Maselli joined Catalent in 2010 as Director of Operations at Catalent’s pharmaceutical, nutritional and cosmetics plant in Aprilia, Italy.
Alessandro Maselli was appointed Catalent’s President and Chief Executive Officer in July 2022. He previously served as the company’s President & Chief Operating Officer since February 2019. Mr. Maselli joined Catalent in 2010 as Director of Operations at Catalent’s pharmaceutical, nutritional and cosmetics plant in Aprilia, Italy.
Catalent’s drug product manufacturing can formulate, fill and package your product into a final vial, syringe or cartridge presentation, making it ready to use for the patient or health care professional.
